ClinicalTrials.gg
CompletedNCT02071082Updated Nov 16, 2018Results posted

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

A Phase 3 interventional study of E/C/F/TAF in HIV and HBV, sponsored by Gilead Sciences. Completed at 24 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
79
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Coinfection with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Coinfection · United States.

Enrollment
6th of 10
79 · median 82
Started
2014
with 2 others
Phase 3
2 of 16
none open now
Registered
9th of 16
by date
Lead sponsor
2 of 16
Gilead Sciences

Among the 16 studies in Coinfection with a site in United States, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2014, is one of 2 in phase 3, and was the 9th registered.

Coinfection

92 studies on the registry are indexed under Coinfection; 12 are open to participants now.

Browse Coinfection studies →

Open to participants now

2 of the 16 studies in Coinfection with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Coinfection studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Coinfection with a site in United States, or all of them as a file.
02

Study summary

This study will assess the efficacy, safety, and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfected adults.

Participants will be enrolled into two cohorts:

  • Cohort 1: HIV/HBV coinfected adults who are HIV treatment-naive and HBV treatment-naive
  • Cohort 2: HIV/HBV coinfected adults who are HIV-suppressed
03

Conditions studied

  • HIV
  • HBV

Browse trials for

Keywords

  • HIV
  • HBV
  • Coinfection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Both Cohorts 1 and 2:

    • The ability to understand and sign a written form, which must be obtained prior to initiation of study procedures
    • / co-infected adult males and non-pregnant and non-lactating females
    • No evidence of hepatocellular carcinoma (HCC) or clinical or imaging evidence of cirrhosis (ascites, variceal bleeding, encephalopathy).

      --- Subjects should have documentation of an abdominal ultrasound in the 12 months prior to screening, or an abdominal ultrasound at screening, demonstrating the absence of cirrhosis and HCC.

    • Acute Hepatitis A virus (HAV) immunoglobulin M (IgM) negative
    • virus (HCV) Ab negative, or HCV Ab positive with negative HCV RNA
    • Hepatitis D virus (HDV) Ab negative, or HDV Ab positive with negative HDV RNA
    • Estimated (eGFR) ≥ 50 mL/min according to the formula
    • of > 200 cells/μL
    • Chronic HBV infection as defined by

      • HBsAg positive for ≥ 6 months Or
      • HBsAg positive at screening and either hepatitis B e antigen (HBeAg) or HBV DNA positive ≥ 6 months Or
      • At screening: positive total hepatitis B core antibody (HBcAb) and negative immunoglobulin M antibody to hepatitis B core antigen (HBcIgM) antibody, and

        • HBsAg positive, or
        • HBeAg positive, or
        • HBV DNA positive
  • Cohort 1 (HIV and HBV treatment naive) only:

    • No current or prior anti-HIV treatment, including antiretroviral medications received for prevention (PrEP), or post exposure prophylaxis (PEP)
    • No current or prior anti-HBV treatment
    • Plasma HIV-1 RNA level ≥ 500 copies/mL at screening
    • Screening HBV DNA ≥ 3 log10 IU/mL and \< 9 log10 IU/mL
  • Cohort 2 (HIV suppressed) only:

    • Receiving current antiretroviral regimen for at least 4 consecutive months
    • No current or prior regimen containing 3 active anti-HBV agents (i.e. cannot be on tenofovir alafenamide (TDF)/emtricitabine (FTC)/Entecavir or TDF/lamivudine(3TC)/Entecavir)
    • Maintained plasma HIV-1 RNA \< 50 copies/mL for 6 consecutive months prior to and at the time of the screening visit. Unconfirmed virologic evaluation of ≥ 50 copies/mL after previously reaching viral suppression (transient detectable viremia, or "blip") and prior to screening is acceptable
    • Documented positive HIV antibody test
    • Screening HBV DNA \< 9 log10 IU/mL

Key Exclusion Criteria:

  • Females who are breastfeeding
  • Positive serum pregnancy test (female of )
  • Have an implanted defibrillator or pacemaker
  • Current alcohol or substance use
  • A history of within the past 5 years (prior to screening) or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive carcinoma.
  • Received solid organ or bone marrow transplant
  • Any history of, or current evidence of, clinical hepatic decompensation (e.g., ascites, encephalopathy or variceal hemorrhage).
  • Significant bone disease (e.g., osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, osteochondroses), or multiple bone fractures
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1
  • Subjects on hemodialysis, other forms of renal replacement therapy, or on treatment for underlying kidney diseases (including prednisolone, and dexamethasone)
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements
  • agents (unless approved by Gilead Sciences). Participation in any other clinical trial without prior approval from the sponsor is prohibited while participating in this trial

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    HIV treatment-naive and HBV treatment-naive

    HIV/HBV coinfected participants who are HIV treatment-naive and HBV treatment-naive will receive E/C/F/TAF for 48 weeks.

    Drug: E/C/F/TAF

  • Experimental
    HIV-suppressed

    HIV/HBV coinfected participants who are HIV-suppressed will receive E/C/F/TAF for 48 weeks.

    Drug: E/C/F/TAF

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  2. Percentage of Participants With Plasma HBV DNA Levels < 29 IU/mL

    The percentage of participants with HBV DNA \< 29 IU/mL at Week 24 was calculated using the missing = failure method.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  2. Percentage of Participants With Plasma HBV DNA Levels < 29 IU/mL

    The percentage of participants with HBV DNA \< 29 IU/mL at Week 48 was calculated using the missing = failure method.

    Time frame: Week 48

  3. Percentage of Participants With Normalized Alanine Aminotransferase (ALT) at Week 24

    ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

    Time frame: Baseline; Week 24

  4. Percentage of Participants With Normalized ALT at Week 48

    ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

    Time frame: Baseline; Week 48

  5. Percentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs) at Week 24

    Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.

    Time frame: Baseline; Week 24

  6. Percentage of Participants With Seroconversion to Anti-HBs at Week 48

    Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.

    Time frame: Baseline; Week 48

  7. Percentage of Participants With Seroconversion to Hepatitis B e Antibody (Anti-HBe) at Week 24

    Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.

    Time frame: Baseline; Week 24

  8. Percentage of Participants With Seroconversion to Anti-HBe at Week 48

    Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.

    Time frame: Baseline; Week 48

  9. Change From Baseline in FibroTest® Score at Week 24

    The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.

    Time frame: Baseline; Week 24

  10. Change From Baseline in FibroTest® Score at Week 48

    The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.

    Time frame: Baseline; Week 48

07

Results

Posted Apr 4, 2016

Participant flow

Participants were enrolled at study sites in North America and Japan. The first participant was screened on 25 February 2014. The last study visit occurred on 26 October 2016.

Participant flow — Overall Study
MilestoneHIV/HBV Treatment-Naive (Cohort 1)HIV-Suppressed (Cohort 2)
Started475
Completed268
Not completed27
Withdrew: Enrolled and never treated11
Withdrew: Adverse event01
Withdrew: Withdrew consent04
Withdrew: Lost to follow-up11

Outcome measures

PrimaryPercentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL
percentage of participantsHIV/HBV Treatment-NaiveHIV-Suppressed
Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL100.094.4
PrimaryPercentage of Participants With Plasma HBV DNA Levels < 29 IU/mL

The percentage of participants with HBV DNA \< 29 IU/mL at Week 24 was calculated using the missing = failure method.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HBV DNA Levels < 29 IU/mL
percentage of participantsHIV/HBV Treatment-NaiveHIV-Suppressed
Percentage of Participants With Plasma HBV DNA Levels < 29 IU/mL33.386.1
SecondaryPercentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL
percentage of participantsHIV/HBV Treatment-NaiveHIV-Suppressed
Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL66.791.7
SecondaryPercentage of Participants With Plasma HBV DNA Levels < 29 IU/mL

The percentage of participants with HBV DNA \< 29 IU/mL at Week 48 was calculated using the missing = failure method.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HBV DNA Levels < 29 IU/mL
percentage of participantsHIV/HBV Treatment-NaiveHIV-Suppressed
Percentage of Participants With Plasma HBV DNA Levels < 29 IU/mL66.791.7
SecondaryPercentage of Participants With Normalized Alanine Aminotransferase (ALT) at Week 24

ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Normalized Alanine Aminotransferase (ALT) at Week 24
percentage of participantsHIV/HBV Treatment-NaiveHIV-Suppressed
Percentage of Participants With Normalized Alanine Aminotransferase (ALT) at Week 24100.050.0
SecondaryPercentage of Participants With Normalized ALT at Week 48

ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

Time frame:
Baseline; Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Normalized ALT at Week 48
percentage of participantsHIV/HBV Treatment-NaiveHIV-Suppressed
Percentage of Participants With Normalized ALT at Week 4866.740.0
SecondaryPercentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs) at Week 24

Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs) at Week 24
percentage of participantsHIV/HBV Treatment-NaiveHIV-Suppressed
Percentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs) at Week 2401.4
SecondaryPercentage of Participants With Seroconversion to Anti-HBs at Week 48

Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.

Time frame:
Baseline; Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion to Anti-HBs at Week 48
percentage of participantsHIV/HBV Treatment-NaiveHIV-Suppressed
Percentage of Participants With Seroconversion to Anti-HBs at Week 4801.4
SecondaryPercentage of Participants With Seroconversion to Hepatitis B e Antibody (Anti-HBe) at Week 24

Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion to Hepatitis B e Antibody (Anti-HBe) at Week 24
percentage of participantsHIV/HBV Treatment-NaiveHIV-Suppressed
Percentage of Participants With Seroconversion to Hepatitis B e Antibody (Anti-HBe) at Week 2433.33.3
SecondaryPercentage of Participants With Seroconversion to Anti-HBe at Week 48

Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.

Time frame:
Baseline; Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion to Anti-HBe at Week 48
percentage of participantsHIV/HBV Treatment-NaiveHIV-Suppressed
Percentage of Participants With Seroconversion to Anti-HBe at Week 4833.30
SecondaryChange From Baseline in FibroTest® Score at Week 24

The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.

Time frame:
Baseline; Week 24
Reported as:
Median · units on a scale
Change From Baseline in FibroTest® Score at Week 24
units on a scaleHIV/HBV Treatment-NaiveHIV-Suppressed
Change From Baseline in FibroTest® Score at Week 24-0.19 (-0.24 to -0.10)-0.02 (-0.12 to 0.04)
SecondaryChange From Baseline in FibroTest® Score at Week 48

The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.

Time frame:
Baseline; Week 48
Reported as:
Median · units on a scale
Change From Baseline in FibroTest® Score at Week 48
units on a scaleHIV/HBV Treatment-NaiveHIV-Suppressed
Change From Baseline in FibroTest® Score at Week 48-0.15 (-0.21 to -0.08)-0.07 (-0.12 to 0.02)

Adverse events

Collected over Up to 126 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HIV/HBV Treatment-Naive0/3 (0%)0/3 (0%)2/3 (66.7%)
HIV-Suppressed0/74 (0%)12/74 (16.2%)51/74 (68.9%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventHIV/HBV Treatment-NaiveHIV-Suppressed
Acute myocardial infarctionCardiac disorders0/31/74
GastritisGastrointestinal disorders0/31/74
Small intestinal obstructionGastrointestinal disorders0/31/74
Chest painGeneral disorders0/31/74
Abscess limbInfections and infestations0/31/74
AppendicitisInfections and infestations0/31/74
Meningitis pneumococcalInfections and infestations0/31/74
Pneumococcal bacteraemiaInfections and infestations0/31/74
PneumoniaInfections and infestations0/31/74
Pneumonia pneumococcalInfections and infestations0/31/74
Most frequent other events
Showing 10 of 19
Most frequent other events
EventHIV/HBV Treatment-NaiveHIV-Suppressed
Dental cariesGastrointestinal disorders1/30/74
DiarrhoeaGastrointestinal disorders1/38/74
VomitingGastrointestinal disorders1/32/74
Herpes zosterInfections and infestations1/31/74
NasopharyngitisInfections and infestations1/39/74
SyphilisInfections and infestations1/33/74
Upper respiratory tract infectionInfections and infestations1/317/74
Gastrooesophageal reflux diseaseGastrointestinal disorders0/37/74
BronchitisInfections and infestations0/36/74
Back painMusculoskeletal and connective tissue disorders0/36/74

Baseline characteristics

Safety Analysis Set: participants who were enrolled and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)HIV/HBV Treatment-NaiveHIV-SuppressedTotal
Mean27 ± 4.049 ± 7.849 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)HIV/HBV Treatment-NaiveHIV-SuppressedTotal
Female066
Male36871
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)HIV/HBV Treatment-NaiveHIV-SuppressedTotal
American Indian or Alaska Native011
Asian279
Black01414
White15051
Other022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)HIV/HBV Treatment-NaiveHIV-SuppressedTotal
Hispanic or Latino01212
Not Hispanic or Latino36265
Region of Enrollment
Region of Enrollment(participants)HIV/HBV Treatment-NaiveHIV-SuppressedTotal
Canada01010
United States16263
Japan224
HIV-1 RNA
HIV-1 RNA(log10 copies/mL)HIV/HBV Treatment-NaiveHIV-SuppressedTotal
Mean4.20 ± 1.2421.29 ± 0.0681.41 ± 0.606
HIV-1 RNA Category
HIV-1 RNA Category(participants)HIV/HBV Treatment-NaiveHIV-SuppressedTotal
< 50 copies/mL07373
≥ 50 copies/mL314
HBV DNA
HBV DNA(log10 IU/mL)HIV/HBV Treatment-NaiveHIV-SuppressedTotal
Mean8.31 ± 0.4161.49 ± 0.8831.75 ± 1.588

5 further baseline measures are reported on the registry.

08

Study locations

24 sites
  • Spectrum Medical Group
    Phoenix, Arizona 85012, United States
  • AHF Research Center
    Beverly Hills, California 90211, United States
  • Peter J. Ruane MD, Inc.
    Los Angeles, California 90036, United States
  • Anthony Mills MD, Inc
    Los Angeles, California 90069, United States
  • Whitman Walker Health
    Washington, District of Columbia 20009, United States
  • Barry M. Rodwick MD
    Clearwater, Florida 33765, United States
  • Gary J Richmond M.D.,P.A.
    Fort Lauderdale, Florida 33316, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34982, United States
  • AIDS Health Foundation/WPA
    Miami Beach, Florida 33139, United States
  • AIDS Research and Treatment Center of the Treasure Coast
    Vero Beach, Florida 32960, United States
  • Triple O Research Institute PA
    West Palm Beach, Florida 33401, United States
  • Be Well Medical Center PC
    Berkley, Michigan 48072, United States
  • KC Care Clinic
    Kansas City, Missouri 64111, United States
  • Southampton Healthcare, Inc.
    Saint Louis, Missouri 63139, United States
  • Southwest CARE Center
    Santa Fe, New Mexico 87505, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • St. Hope Foundation
    Bellaire, Texas, United States
  • North Texas Infectious Diseases Consultants
    Dallas, Texas 75246, United States
  • Therapeutic Concepts
    Houston, Texas 77004, United States
  • Gordon E. Crofoot MD PA
    Houston, Texas 77098, United States
  • Peter Shalit MD
    Seattle, Washington 98104, United States
  • University Health Network/Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • Maple Leaf Research/Maple Leaf Medical Clinic
    Toronto, Ontario M5G1K2, Canada
  • Center Hospital of the National Center for Global Health and Medicine
    Shinjuku-ku, Tokyo 1628655, Japan
09

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2014 to primary completion in Jan 2015, 10 months.

Results were first posted in Apr 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2014
First posted
Feb 25, 2014
StartActual
Feb 25, 2014
Primary completionActual
Jan 23, 2015
CompletionActual
Oct 26, 2016
Results first posted
Apr 4, 2016
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02071082
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 25, 2014
Start date
Feb 25, 2014
Primary completion
Jan 23, 2015
Completion
Oct 26, 2016
Results posted
Apr 4, 2016
Last update
Nov 16, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion